# Cough Reduction in IPF With Nalbuphine ER

> **NCT05964335** · PHASE2 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 165 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Placebo
- **DRUG:** NAL ER
- **DRUG:** NAL ER

## Key facts

- **NCT ID:** NCT05964335
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-04-24
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964335, "Cough Reduction in IPF With Nalbuphine ER". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05964335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*